Unlike other proteins, ICAM‐1 overexpression in TNBC positively correlates with immunotherapy efficacy.[16] Recent studies revealed that the expression levels of ICAM‐1 in murine models of melanoma and colon cancer were significantly correlated with the therapeutic efficacy of immune checkpoint inhibitors,[17] suggesting a potential synergistic effect between these immunotherapeutic strategies, potentially leading to improved therapeutic outcomes. This evidence concerns the gene ICAM1 and melanoma.